Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Documenti analoghi

• Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
  di: Cufí, Sílvia, et al.
  Pubblicazione: (2012)
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
  di: Kim, Hwang-Phill, et al.
  Pubblicazione: (2009)
• The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
  di: Cufí, Sílvia, et al.
  Pubblicazione: (2013)
• Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions
  di: Vazquez-Martin, Alejandro, et al.
  Pubblicazione: (2011)
• Metformin-induced preferential killing of breast cancer initiating CD44(+)CD24(−/low) cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
  di: Cufí, Sílvia, et al.
  Pubblicazione: (2012)